How HCMV uses the body's signaling system to persist in the host
Official title: HCMV stimulation of interferon signaling to promote viral gene expression and latency
Funded at University of Arizona · NIH-10995193 · Data updated 2026-11-12
This study is looking at how the human cytomegalovirus (HCMV) tricks the body's immune system to stay hidden and inactive, which could help find new ways to treat HCMV infections, especially for people with weakened immune systems.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project start | November 1, 2024 |
| Project end | October 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $74,284 |
| NIH project number | 1F32AI186281-01 |
| Project ID | NIH-10995193 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who are immunocompromised or have a history of HCMV infection.
✕Less likely to help
Patients who are immunocompetent and do not have a history of HCMV infection are unlikely to benefit from this research.
What this research studies
This research investigates how the human cytomegalovirus (HCMV) manipulates the body's interferon signaling pathways to establish and maintain a state of latency, which is a dormant phase of infection. By studying the interactions between viral proteins and host cellular factors, the research aims to understand the mechanisms that allow HCMV to evade the immune response. The approach involves examining how HCMV keeps certain signaling proteins active for extended periods, which is crucial for its persistence in the body. This could provide insights into potential therapeutic targets for treating HCMV infections, especially in immunocompromised individuals.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing or treating HCMV infections, particularly in vulnerable populations.
How similar studies have gone: Previous research has shown that targeting viral manipulation of host signaling pathways can be effective, suggesting that this approach may yield valuable insights.
Where this research is happening
-
University of Arizona
Tucson, United States Active
Researchers
- Principal investigator: White, Timothy M — University of Arizona
- Study coordinator: White, Timothy M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.